LOS ANGELES — Syncor International Corp., Chatsworth, announced the sale of its Berkeley-based California Integrated Diagnostics unit to InFerGene Co. of Benicia, Calif., a biotech company specializing in DNA technology for the manufacture of enzymes for the food and brewing industries and the medical diagnostics field.
California Integrated Diagnostics, which develops and markets rapid detection diagnostic kits for sexually transmitted diseases, was acquired in exchange for approximately 350,000 shares of InFerGene common stock. The transaction now makes Syncor International a holder of approximately 6% of the total outstanding shares of InFerGene.
California Integrated Diagnostics currently markets diagnostic kits for rapid detection of Chlamydia and Trichomonas and plans to introduce a third test for Herpes I and II later in 1987, after certain FDA clearances have been received.
Syncor International operates a nationwide network of pharmacy service centers that prepare and deliver advanced pharmaceuticals, primarily radioactive compounds, to 5,000 hospitals and clinics.